• Kirsten de Groot, Peer Malte Aries, Marion Haubitz, Bernhard Hellmich, Peter Lamprecht, and Jens Thiel.
• Medizinische Klinik III (Nephrologie, Dialyse, Hypertensiologie, Rheumatologie), Klinikum Offenbach GmbH und KfH-Nierenzentrum Offenbach/Main.
• Dtsch. Med. Wochenschr. 2020 Jan 1; 145 (1): 40-46.

AbstractGranulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are the most frequent primary necrotizing small vessel vasculitides. In these formerly fatal diseases remission can be induced by stage- and activity-adapted immunosuppressive regimens in the majority of patients. This does not lead to drug-free long-term remission or even cure. Consequently, maintenance of remission medication is needed. Recent randomized controlled trials demonstrated that maintenance treatment with the anti-B-cell antibody Rituximab, administered 6-monthly as opposed to azathioprine leads to a significantly lower relapse rate but a similar profile of adverse events. These data enabled the extension of the approval of Rituximab for maintenance of remission treatment of GPA and MPA in Germany in 2018. Guidelines and expert recommendations concerning measures of infection prevention and vaccination of immunosuppressed patients as well as the management of hypogammaglobulinemia and cytopenia on Rituximab are presented in this review.© Georg Thieme Verlag KG Stuttgart · New York.

12 keywords...

hide…